Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma 計劃將發行的淨收益用於 NXC-201 臨床試驗、營運資金、一般用途 >IMMX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊